Pancreatic Cancer Research

ResearcherGifu University HospitalActive in the last 2 years

Masahito Shimizu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1151-2058; OpenAlex author ID A5005286789, A5054533666. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2016: 3 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: 6 papers · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 27

  1. 11.5-Fr Large-Bore Plastic Stents Versus Fully Covered Self-Expandable Metallic Stents for the Management of Preoperative Endoscopic Biliary Obstruction in Pan… Last author DOI 10.1007/s10620-026-10136-z↗
  2. Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced pancreatic cancer: A single-center randomized con… Last author DOI 10.1016/j.clnesp.2026.103106↗
  3. Development of Pancreatic Cancer during the Follow-up of Autoimmune Pancreatitis: A Report of Two Cases. Last author DOI 10.2169/internalmedicine.2086-23↗
  4. Exosome Transfer Between Different Co-implanted Human Pancreatic Cancer Cell Lines Occurs in the Primary Tumor and Multiple Metastatic Sites of Nude Mice But N… Co-author DOI 10.21873/anticanres.17149↗
  5. Pretherapeutic factors predicting conversion surgery in unresectable pancreatic ductal adenocarcinoma: A retrospective study. Co-author DOI 10.3892/ol.2024.14304↗
  6. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective … Co-author DOI 10.1007/s00520-023-08136-0↗
  7. Drainage of Afferent Limb Obstruction via the Trans-gastric-bile Duct Formed after Endoscopic Ultrasound-guided Hepaticogastrostomy in a Patient with Pancreati… Last author DOI 10.2169/internalmedicine.1002-22↗
  8. Impact of Controlling nutritional status (CONUT) in patients with unresectable advanced pancreatic cancer receiving multi-agent chemotherapy: A single center, … Last author DOI 10.1016/j.pan.2022.01.010↗
  9. The efficacy and safety of modified FOLFIRINOX for unresectable advanced pancreatic cancer in elderly versus young patients: A multicenter retrospective cohort… Last author DOI 10.1016/j.pan.2022.11.005↗
  10. Covered self-expandable metallic stent versus plastic stent for preoperative endoscopic biliary drainage in patients with pancreatic cancer: a multi-center ret… Last author DOI 10.1080/00365521.2021.2015802↗
  11. Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer. Co-author DOI 10.3390/jcm11195895↗
  12. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Last author DOI 10.1017/s0007114520003463↗
  13. Evaluation of preoperative diagnostic methods for resectable pancreatic cancer: a diagnostic capability and impact on the prognosis of endoscopic ultrasound-gu… Last author DOI 10.1186/s12876-021-01955-7↗
  14. Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient che… Co-author DOI 10.1186/s40780-021-00210-1↗
  15. Exosome Transfer Between Pancreatic-cancer Cells Is Associated With Metastasis in a Nude-mouse Model. Co-author DOI 10.21873/anticanres.15063↗
  16. Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients… Co-author DOI 10.21873/anticanres.15154↗
  17. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Cen… Last author DOI 10.3390/jcm10132848↗
  18. Color-coded Imaging of the Fate of Cancer-cell-derived Exosomes During Pancreatic Cancer Metastases in a Nude-mouse Model. Co-author DOI 10.21873/anticanres.13561↗
  19. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. Last author DOI 10.3390/jcm8060761↗
  20. Endoscopic duodenal stent versus surgical gastrojejunostomy for gastric outlet obstruction in patients with advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2018.04.015↗
  21. Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models. Co-author DOI 10.21873/anticanres.12430↗
  22. Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy. Co-author DOI 10.3390/cancers10110454↗
  23. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Last author DOI 10.18632/oncotarget.22795↗
  24. Imaging the Role of Multinucleate Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in Peritoneal Metastasis in Mouse Models. Co-author DOI 10.21873/anticanres.11711↗
  25. The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.7424↗
  26. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. Co-author DOI 10.3390/ijms17010137↗
  27. Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells. Co-author DOI 10.3892/ol.2016.4564↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuji Iwashita · 20 shared papers, 2016–2026 · strength 3.07
  2. Shinya Uemura · 17 shared papers, 2017–2026 · strength 2.64
  3. Hironao Ichikawa · 7 shared papers, 2021–2026 · strength 1.26
  4. Akinori Maruta · 6 shared papers, 2017–2026 · strength 1.08
  5. Naoki Mita · 5 shared papers, 2019–2026 · strength 0.82
  6. Atsushi Suetsugu · 5 shared papers, 2017–2024 · strength 0.68
  7. Robert M. Hoffman · 5 shared papers, 2017–2024 · strength 0.68
  8. Mitsuru Okuno · 6 shared papers, 2016–2026 · strength 0.68
  9. Koichi Ohata · 5 shared papers, 2018–2023 · strength 0.67
  10. Akio Suzuki · 5 shared papers, 2018–2023 · strength 0.67
  11. Kensaku Yoshida · 5 shared papers, 2017–2022 · strength 0.61
  12. Shiori Sadaka · 4 shared papers, 2021–2023 · strength 0.59
  13. Ichiro Yasuda · 6 shared papers, 2016–2022 · strength 0.56
  14. Ryuichi Tezuka · 3 shared papers, 2022–2024 · strength 0.55
  15. Hironori Fujii · 4 shared papers, 2018–2022 · strength 0.48
  16. Seiji Adachi · 4 shared papers, 2016–2023 · strength 0.38
  17. Hisataka Moriwaki · 5 shared papers, 2016–2019 · strength 0.37
  18. Tomoyuki Satake · 3 shared papers, 2018–2021 · strength 0.33
  19. Koji Yamashita · 1 shared paper, 2024 · strength 0.28
  20. Osamu Kozawa · 3 shared papers, 2016 · strength 0.19
  21. Masatoshi Mabuchi · 1 shared paper, 2023 · strength 0.18
  22. Toshiya Higashi · 1 shared paper, 2024 · strength 0.18
  23. Nobuhisa Matsuhashi · 1 shared paper, 2024 · strength 0.18
  24. Masahiro Fukada · 1 shared paper, 2024 · strength 0.18
  25. Junji Kawaguchi · 3 shared papers, 2016–2017 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.